LAFFON, Eric; DE CLERMONT-GALLERANDE, Henri; MARTHAN, Roger

doi:10.1186/s13550-021-00814-6

Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] [CRCTB]

DE CLERMONT-GALLERANDE, Henri

MARTHAN, Roger

Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] [CRCTB]

Idioma

Article de revue

Este ítem está publicado en

EJNMMI Research. 2021-08-21, vol. 11, n° 1

Resumen en inglés

In a preclinical model of neuroblastoma, Dearling et al. recently demonstrated the potential interest for a theranostic approach of [64/67Cu]Cu-SARTATE for the detection and treatment of SSTR2-positive neuroblastoma lesions in pediatric patients whose widespread metastases survive initial therapy as minimal residual disease (MRD). MRD may be detected by [64Cu]Cu-SARTATE and subsequently treated by [67Cu]Cu-SARTATE. Since therapeutic dosimetry estimation of the latter agent from the uptake of the former one in the initial diagnostic scan was not addressed, the present theoretical commentary proposes the derivation of an abbreviated therapy-dosimetric equation for the companion diagnostic/therapeutic [64/67Cu]Cu-SARTATE that might be of interest for future clinical theranostic practice.< Leer menos

Palabras clave en inglés

Cumulated activity

Dosimetry

Neuroblastoma

SARTATE

Theranostics

URI

https://oskar-bordeaux.fr/handle/20.500.12278/151977

DOI

http://dx.doi.org/10.1186/s13550-021-00814-6

Centros de investigación

Centre de Recherche Cardio-Thoracique de Bordeaux (CRCTB) - U1045

Ver/Abrir

Metadatos

Compartir este ítem

Licencia de uso del documento

An abbreviated therapy-dosimetric equation for the companion diagnostic/therapeutic [64/67Cu]Cu-SARTATE

Idioma

Este ítem está publicado en

Resumen en inglés

Palabras clave en inglés

URI

DOI

Centros de investigación